Evidence map›Paper›PMID 36680103›Full record

ReviewViruses2022

Hepatitis E Virus (HEV) Synopsis: General Aspects and Focus on Bangladesh.

Asma Binte Aziz, Joakim Øverbø, Susanne Dudman, Cathinka Halle Julin, Yoon Jeong Gabby Kwon, Yasmin Jahan, Mohammad Ali, Jennifer L Dembinski

Open access · goldAbstract readReview
In one paragraph

Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Asma Binte AzizInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0003-0203-5744
Joakim ØverbøInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0002-1773-1622
Susanne DudmanInstitute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.ORCID 0000-0001-5047-4982
Cathinka Halle JulinNorwegian Institute of Public Health (NIPH), Division of Infection Control and Environmental Health, 0213 Oslo, Norway.ORCID 0000-0002-3934-7410
Yoon Jeong Gabby KwonCarnegie Mellon University, Pittsburgh, PA 15213, USA.
Yasmin JahanGraduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-0046, Japan.ORCID 0000-0001-9273-9651
Mohammad AliJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, MD 21205, USA.ORCID 0000-0003-1410-388X
Jennifer L DembinskiNorwegian Institute of Public Health (NIPH), Division of Infection Control and Environmental Health, 0213 Oslo, Norway.ORCID 0000-0001-9259-9572
Norwegian Institute of Public Health · NOCarnegie Mellon University · USHiroshima University · JPInternational Vaccine Institute · KRJohns Hopkins University · USUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HEV is the most common cause of acute hepatitis globally. This review summarizes the latest knowledge on the epidemiology, clinical characteristics, testing, and treatment of HEV infection. We also focused on Bangladesh to highlight the distinct challenges and the possible remedies. In low-income settings, the virus is mainly transmitted between people by fecal contamination of drinking water causing large outbreaks, and sporadic cases. The disease is usually mild and self-limiting acute hepatitis. Still, pregnant women and their offspring in low-income countries are at particular risk for severe disease, with up to 20% maternal mortality. Despite the high burden of the disease, HEV remains a relatively neglected virus, with detection hampered by costly tests and a lack of suitable treatments. Molecular PCR diagnostics, together with ELISA antibody tests, remain the preferred methods for diagnosis of HEV; however, rapid bedside diagnostics are available and could offer a practical alternative, especially in low-income countries. One vaccine (HEV 239) is only available in China and Pakistan, as efficacy against the other genotypes remains uncertain. The effectiveness trial conducted in Bangladesh might lead the way in gathering more efficacy data and could, together with improved surveillance and raised awareness, dramatically reduce the global burden of HEV.

Indexed as

Hepatitis EHepatitis E virusAcute DiseaseBangladeshDisease OutbreaksFemaleGenotypeHumansPregnancyBangladeshendemic zonesepidemiologyhepatitis E virus (HEV)vaccine

Identifiers

PMID36680103
PMCPMC9866510
OpenAlexW4313413773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.